# A Study to Investigate the PK and Safety of CKD-393

> **NCT04768673** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 26 (actual)

## Conditions studied

- Type II Diabetes

## Interventions

- **DRUG:** CKD-393 formulation I
- **DRUG:** CKD-393 formulation II
- **DRUG:** D501, D759, H053

## Key facts

- **NCT ID:** NCT04768673
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-26
- **Primary completion:** 2021-04-22
- **Final completion:** 2021-04-27
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04768673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04768673, "A Study to Investigate the PK and Safety of CKD-393". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04768673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*